Dr Paul de Souza from New South Wales, Australia, discusses how close we are to personalising treatment in patients with prostate cancer. He explores what the concept of personalised medicine really means, and the biomarkers being considered in prostate cancer in this regard. He explores the process for biomarker development, and also notes the challenges of personalised care in prostate cancer.

This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson